Pinealon (Glu-Asp-Arg, or EDR) is a tripeptide bioregulator developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology in Russia. It belongs to a class of ultra-short peptides — typically two to four amino acids in length — that Khavinson's research group has identified as tissue-specific gene regulators capable of modulating protein expression in target tissues at remarkably low concentrations.

Pinealon is the brain-specific bioregulator in the Khavinson system. Its proposed mechanism involves direct interaction with DNA in neuronal cells, where the tripeptide sequence binds to specific gene promoter regions and modulates the expression of proteins involved in neuronal survival, differentiation, and function. In cell culture and animal studies, Pinealon has demonstrated the ability to increase the expression of neurotrophic factors, modulate serotonin and melatonin synthesis in pineal cells, and protect neurons against oxidative damage and excitotoxicity.

The bioregulator concept differs fundamentally from conventional pharmacology. Rather than binding a receptor and triggering a signaling cascade (the mechanism of most peptide drugs), bioregulators are proposed to function as epigenetic modulators — normalizing gene expression patterns that have drifted from their youthful state due to aging, stress, or disease. The doses are ultra-low, the effects are slow to develop, and the clinical evidence comes primarily from Russian research institutions with limited independent replication in Western literature.

This context is important for setting expectations. Pinealon is not a nootropic stimulant that produces acute cognitive enhancement. It is a putative gene-regulatory peptide aimed at gradually restoring optimal neuronal function over weeks to months of consistent use.

Dose selection

Oral/sublingual dose (capsule or sublingual tablet): 10-20 mg per day, taken as a single dose or divided into two doses.

Sublingual solution: If using reconstituted Pinealon sublingually, typical doses are 200-500 mcg held under the tongue for 60-90 seconds before swallowing. The sublingual route provides partial absorption through the oral mucosa, bypassing first-pass hepatic metabolism. However, even with oral administration, the tripeptide's small size (three amino acids) allows for some intact absorption through the gastrointestinal tract — a significant advantage over larger peptides that are completely degraded.

Starting dose: Begin at the lower end of the applicable range. For capsules, 10 mg daily. For sublingual solution, 200 mcg daily. Assess for 2 weeks before increasing.

Dose ceiling: Bioregulator theory emphasizes that ultra-low doses are both sufficient and optimal. Unlike most pharmacological agents where higher doses produce stronger effects up to a ceiling, bioregulators are proposed to work through gene-regulatory mechanisms that are fully activated at very low peptide concentrations. Exceeding the recommended dose range is not expected to enhance effects and is discouraged.

Timing and administration

Route options:

Oral capsules are the most convenient form and the most widely available through Russian and European supplement channels. Take with water on an empty stomach — 30 minutes before food or 2 hours after eating. While the tripeptide's small size affords some protection against complete digestive degradation, an empty stomach minimizes exposure to digestive enzymes and maximizes the proportion of intact peptide reaching the bloodstream.

Sublingual solution offers improved bioavailability compared to swallowed capsules. Prepare by dissolving the appropriate dose in a minimal volume of water. Hold under the tongue for 60-90 seconds, allowing absorption through the sublingual mucosa. Do not eat or drink for 15 minutes after administration.

Timing within the day: Morning administration is standard, aligning with the daily peak of cognitive demand and cortisol-driven neuronal activity. If splitting the dose (e.g., 10 mg morning and 10 mg early afternoon for capsule form), the second dose should be taken before 3 PM to align with the natural circadian rhythm of cognitive function rather than opposing it.

No injection required: Unlike most peptide protocols, Pinealon does not require subcutaneous injection. Its three-amino-acid structure is small enough for oral bioavailability, which is a significant practical advantage for long-term compliance.

Cycle structure

Standard Khavinson cycle: 10-20 days on, followed by a 3-6 month pause before the next course.

This cycling pattern is distinctive and reflects the bioregulator theory of action. The hypothesis is that the short course of ultra-low-dose peptide exposure initiates a gene-regulatory cascade that continues to develop and mature over the months following the active dosing period. The peptide provides the initial epigenetic signal; the cellular machinery carries the effect forward long after the peptide has been cleared from the body.

Practical cycling approach: Many practitioners outside the Russian bioregulator tradition extend the active phase to 30 days, reasoning that a longer exposure period provides a stronger regulatory signal. A 30-day active phase followed by a 2-3 month pause is a common modified cycle.

Annual pattern: In the Khavinson system, bioregulator courses are typically administered 2-4 times per year. For Pinealon, a schedule of one 20-30 day course every 3 months provides four annual cycles — consistent with the original clinical research protocols.

Cycling with other Khavinson peptides: Pinealon is often used as part of a multi-bioregulator program targeting different organ systems. Common combinations in the Khavinson system include Pinealon (brain) with Visoluten (eyes), Chonluten (respiratory mucosa), and Crystagen (immune system). When using multiple bioregulators, they can be taken simultaneously during the active phase — each targets different gene sets in different tissues, so there is no competition for the same regulatory mechanisms.

Monitoring

Cognitive assessment:

Formal cognitive testing provides the most reliable assessment of Pinealon's effects, though the gradual nature of bioregulatory changes makes short-term testing less informative than longer-term tracking.

Baseline assessment (before first course): Administer a standardized cognitive assessment — the Montreal Cognitive Assessment (MoCA), Trail Making Test, or a digital cognitive battery (such as Cambridge Brain Sciences or BrainHQ). Record scores across domains: memory, attention, processing speed, executive function, and visuospatial ability.

Follow-up assessment: Repeat at the end of the active phase and again 2-3 months later (during the pause, when bioregulatory effects are proposed to be developing). The key comparison is not before-versus-after the active phase, but baseline-versus-months-later, reflecting the delayed-onset theory of bioregulator action.

Subjective daily tracking: During the active phase and for 4-6 weeks after, maintain a brief daily log of cognitive clarity, memory recall, mood, sleep quality, and mental energy. Rate each on a 1-10 scale at a consistent time (midday recommended). Look for gradual trends rather than day-to-day fluctuations.

Biomarkers (optional but informative):

BDNF (brain-derived neurotrophic factor) — if Pinealon upregulates neurotrophic factor expression as proposed, serum BDNF may increase over the course of treatment
Cortisol (morning, 30 minutes after waking) — chronic stress-driven cortisol elevation impairs hippocampal function; any normalizing effect of Pinealon on stress physiology would be reflected here
Melatonin (nighttime salivary sampling) — given Pinealon's connection to pineal function, changes in melatonin production are a relevant marker, though difficult to measure practically

Common combinations

Pinealon + Cortagen (brain + cortex-specific bioregulator): Cortagen is another Khavinson peptide targeting the cerebral cortex. While Pinealon is associated with pineal and general neuronal function, Cortagen is proposed to target cortical neurons specifically. This combination addresses different neuronal populations and is the standard Khavinson cognitive stack.

Pinealon + Selank (200-500 mcg intranasal, cycled): Selank provides acute anxiolytic and cognitive-enhancing effects through GABA and BDNF modulation, while Pinealon provides putative long-term gene-regulatory support. This combination addresses both the acute performance and the long-term maintenance dimensions of cognitive health. Use Selank during periods of high cognitive demand within or between Pinealon courses.

Pinealon + Semax (200-600 mcg intranasal, cycled): Semax provides acute cognitive activation through dopaminergic and BDNF mechanisms. Like the Selank combination, this pairs acute nootropic effects with long-term bioregulation. Semax is more activating and focus-oriented than Selank, making it preferable for individuals whose primary cognitive need is concentration and processing speed rather than anxiety-buffered performance.

Pinealon + Epitalon (5-10 mg subcutaneously, 10-20 day courses): Epitalon is the Khavinson peptide targeting the pineal gland for melatonin regulation and telomerase activation. The Pinealon-Epitalon combination addresses brain health from both the neuronal (Pinealon) and neuroendocrine/pineal (Epitalon) perspectives. Both peptides follow the same short-course cycling pattern, making them practical to administer in the same treatment window.

Contraindications and cautions

Limited safety data: Pinealon's safety profile is derived primarily from Russian clinical and preclinical studies. While no significant adverse effects have been reported at recommended doses, the evidence base is narrower than for peptides with international clinical trial data. Use cautiously and monitor for any unexpected effects.

Autoimmune neurological conditions: Given Pinealon's proposed gene-regulatory effects on neuronal tissue, individuals with autoimmune conditions affecting the nervous system (multiple sclerosis, neuromyelitis optica, autoimmune encephalitis) should consult their neurologist before use. Modulating neuronal gene expression in the context of active autoimmune neuroinflammation could have unpredictable consequences.

Concurrent psychotropic medications: Pinealon's effects on serotonin and melatonin synthesis pathways could theoretically interact with SSRIs, MAOIs, or other serotonergic medications. While no specific interactions have been documented, individuals on psychotropic medications should inform their prescribing physician.

Children and adolescents: No safety data exists for developing brains. The neurodevelopmental implications of exogenous gene-regulatory peptides in individuals whose brain development is still active are unknown.

Pregnancy and breastfeeding: Contraindicated due to insufficient safety data and the theoretical risks of gene-regulatory peptides during fetal development.

Expected timeline

Days 1-20 (active phase): Subtle or no acute effects expected during the dosing period. Some users report mild improvements in dream vividness, sleep quality, or a general sense of mental clarity during the active phase, but these are inconsistent and may reflect placebo response. The bioregulator model explicitly does not predict acute effects — the peptide is initiating gene-regulatory changes that develop over time.

Weeks 3-8 (early post-course): The first signs of cognitive improvement may begin to emerge during this period as the gene-regulatory changes initiated during the active phase mature. Improved memory recall, slightly faster processing speed, and enhanced cognitive resilience under stress are the most commonly reported early effects.

Months 2-4 (full development): Peak effects of a single Pinealon course are proposed to manifest during this window. Cognitive assessment scores, if tracked, should show their maximum improvement relative to baseline during this period. This is the optimal time to perform follow-up cognitive testing.

Months 4-6 (assessment and next course): Effects may begin to gradually diminish as the epigenetic changes initiated by Pinealon slowly revert to the pre-treatment state. This is the rationale for repeat courses — each cycle reinforces the gene-regulatory pattern, and over multiple annual courses, the cumulative effect is proposed to become more durable.

If no cognitive improvement is documented after two complete courses (including the post-course development periods), Pinealon may not be effective for that individual. Consider alternative cognitive enhancement strategies or investigate whether underlying factors (sleep quality, metabolic health, chronic inflammation) are limiting the response to bioregulatory intervention.